Triazolone compounds and uses thereof
The invention disclosed herein is directed to compounds of Formula (1a) and (1b) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocyticδ leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (1a) or (1b), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a compound which is a dual antagonist of PPARα and PPARδ. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a therapeutically effective amount of a dual antagonist of PPARα and PPARδ.
1. A compound of Formula Ib
or a pharmaceutically acceptable salt thereof wherein:
A1 is phenyl;
A2 is A2a
wherein A2 is phenyl or pyridine;
X is —(CH 2 ) m , wherein m is 2, 3 or 4;
R 1 , R 2 and R 9 are each independently selected from the group consisting of hydrogen, halogen, —CF 3 , and —C 1-6 alkyl;
R 3 is selected from the group consisting of:
(a) hydrogen,
(b) halogen,
(c) —CN,
(d) —CF 3 ,
(e) —C 1-6 alkyl,
(f) —C 1-6 alkyl-C(═O)OH,
(g) —O—(R 8 ), and
(h) —N(R 7 )(R 8 ),
wherein the alkyl portion of choices (e) and (f) are optionally substituted with halogen, oxo or hydroxyl;
R 4 is selected from the group consisting of:
(a) hydrogen,
(b) —N(R 7 )S(═O) 2 R 8 ,
(c) —O—R 8 ,
(d) —C 1-6 alkyl-C(═O)OH, and
(e) —C(═O)OH,
with the proviso that at least one of R 3 and R 4 is other than hydrogen;
R 5 is selected from the group consisting of:
(a) —C 1-6 alkyl,
(b) —C 1-4 alkyl(R 7 ),
(c) —aryl,
(d) —heteroaryl, and
(e) —C 3-6 cycloalkyl,
wherein the alkyl portion of choices (a) and (b) is optionally substituted with halogen, the cycloalkyl portion of choice (e) is optionally substituted with halogen or —C 1-6 alkyl, and wherein the aryl of choice (c) and the heteroaryl of choice (d) are optionally mono- or di-substituted with substituents selected from the group consisting of halogen, —C 1-6 alkyl, —CF 3 ,—C 1-6 alkoxy, haloC 1-6 alkyl, —C 3-6 cycloalkyl, and —C 3-6 cycloalkoxy;
R 6 is aryl, optionally mono- or di-substituted with substituents selected from the group consisting of halogen, nitro, —CF 3 , —OCF 3 , —C 1-6 alkyl, —C 1-6 alkoxy, and haloC 1-6 alkyl;
R 7 and R 8 are each independently selected from the group consisting of:
(a) hydrogen,
(b) —C 1-6 alkyl,
(c) —C 3-6 cycloalkyl,
(d) aryl, and
(e) heteroaryl,
wherein the alkyl portion of choice (b) and the cycloalkyl portion of choice (c) are each optionally mono-, di- or tri-substituted with halogen, hydroxyl, —C 1-6 alkyl, —C 1-6 alkoxy, —C 3-6 cycloalkyl or —C 3-6 cycloalkoxy, and wherein the aryl portion of choice (d) and the heteroaryl portion of choice (e) are each optionally mono- or di-substituted with substituents selected from the group consisting of halogen, —C 1-6 alkyl, —C 1-6 alkyl, haloC 1-6 alkyl, —C 3-6 cycloalkyl, —C 3-6 cycloalkoxy, —C(═O)C 1-4 alkyl, hydroxyl, CN, and —(C═O)OH.
2. A compound according to claim 1 or a pharmaceutically acceptable salt thereof wherein:
R 1 , R 2 and R 9 are each independently selected from the group consisting of: hydrogen, halogen, and —C 1-6 alkyl;
R 3 is selected from the group consisting of:
(a) hydrogen,
(b) —CF 3 ,
(c) —C 1-4 alkyl, and
(d) —O—(R 8 ),
wherein the alkyl portion of choice (c) is optionally substituted with halogen, oxo or hydroxyl;
R 4 is selected from the group consisting of:
(a) hydrogen,
(b) —O—(R 8 ),
(c) —C 1-6 alkyl-C(═O)OH,
and
(d) —C(═O)OH,
R 5 is selected from the group consisting of:
(a) —C 1-6 alkyl,
(b) —C 1-4 alkyl(R 7 ),
(c) —aryl,
(d) —heteroaryl, and
(e) —C 3-6 cycloalkyl,
wherein the alkyl portion of choices (a) and (b) is optionally substituted with halogen, the cycloalkyl portion of choice (e) is optionally substituted with C 1-6 alkyl, and wherein the aryl of choice (c) and the heteroaryl of choice (d) are optionally mono- or di-substituted with substituents selected from the group consisting of halogen, —C 1-6 alkyl, —CF 3 , —C 1-6 alkoxy, haloC 1-6 alkyl, —C 3-6 cycloalkyl, and —C 3-6 cycloalkoxy;
R 7 and R 8 are each independently selected from the group consisting of:
(a) hydrogen,
(b) —C 1-6 alkyl, and
(c) aryl, and
wherein the alkyl portion of choice (b) is optionally mono-, di- or tri-substituted with halogen, hydroxyl, —C 1-6 alkyl, —C 1-6 alkoxy, —C 3-6 cycloalkyl or —C 3-6 cycloalkoxy, wherein the aryl portion of choice (c) is optionally mono- or di-substituted with substituents selected from the group consisting of halogen, —C 1-6 alkyl, —C 1-6 alkoxy, haloC 1-6 alkyl, —C 3-6 cycloalkyl, and —(C═O)OH.
3. The compound according to claim 2 , or a pharmaceutically acceptable salt thereof, wherein X is —CH 2 CH 2 CH 2 —.
4. The compound according to claim 2 , or a pharmaceutically acceptable salt thereof, wherein: R 1 , R 2 and R 9 are each independently selected from the group consisting of:
hydrogen and methyl.
5. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein: R 3 is selected from the group consisting of:
(a) hydrogen,
(b) —CF 3 ,
(c) —C 1-4 alkyl, and
(d) —O—(R 8 ),
wherein the alkyl portion of choice (c) is optionally substituted with halogen, oxo or hydroxyl.
6. The compound according to claim 5 , or a pharmaceutically acceptable salt thereof, wherein: R 3 is selected from the group consisting of: hydrogen and —O—(R 8 ).
7. The compound according to claim 2 , or a pharmaceutically acceptable salt thereof, wherein: R 4 is selected from the group consisting of:
(a) hydrogen,
(b) —C 1-6 alkyl-C(═O)OH, and
(c) —C(═O)OH.
8. The compound according to claim 7 , or a pharmaceutically acceptable salt thereof, wherein: R 4 is selected from the group consisting of:
(a) hydrogen, and
(b) —CH 2 —C(═O)OH.
9. The compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein: R 5 is selected from the group consisting of:
(a) —C 1-4 alkyl,
(b) pyridinyl,
(c) phenyl, and
(d) —C 3-6 cycloalkyl,
wherein the cycloalkyl portion of choice (d) is optionally substituted with methyl, and wherein the pyridinyl of choice (b) and the phenyl of choice (c) are optionally mono- or di-substituted with substituents selected from the group consisting of halogen, —C 1-6 alkyl, —CF 3 , C 1-6 alkoxy and haloC 1-6 alkyl.
10. The compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein: R 6 is aryl, optionally mono- or di-substituted with halogen, —CF 3 or —C 1-4 alkyl.
11. The compound according to claim 10 or a pharmaceutically acceptable salt thereof, wherein: R 6 is phenyl optionally mono- substituted with halogen, —CF 3 , or —C 1-4 alkyl.
12. The compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein: R 7 is selected from hydrogen and methyl; and R 8 is selected from hydrogen, C 1-4 alkyl optionally substituted with halogen, and phenyl optionally mono or di-substituted with substituents selected from the group consisting of halogen, —C 1-6 alkyl, —C 1-6 alkoxy, and haloC 1-6 alkyl.
13. The compound according to claim 1 of Formula Ib
or a pharmaceutically acceptable salt thereof, wherein:
X is —CH 2 CH 2 CH 2 —;
A1 is phenyl;
A2 is
R 1 , R 2 and R 9 are each independently selected from the group consisting of
(a) hydrogen,
(b) —CF 3 , and
(c) —C 1-6 alkyl;
R 3 is selected from the group consisting of:
(a) hydrogen,
(b) —CF 3 ,
(c) —C 1-4 alkyl, and
(d) —O—(R 8 ),
wherein the alkyl portion of choice (c) is optionally substituted with halogen, oxo or hydroxyl;
R 4 is selected from the group consisting of:
(a) hydrogen,
(b) —N(R 7 )S(═O) 2 R 8 ,
(c) —C 1-6 alkyl-C(═O)OH, and
(d) —C(═O)OH;
R 5 is selected from the group consisting of:
(a) —C 1-4 alkyl,
(b) heteroaryl,
(c) phenyl, and
(d) —C 3-6 cycloalkyl,
wherein the cycloalkyl portion of choice (d) is optionally substituted with methyl, and wherein the heteroaryl of choice (b) and the phenyl of choice (c) are optionally mono- or di-substituted with substituents selected from the group consisting of halogen, —C 1-6 alkyl, —CF 3 , —C 1-6 alkoxy and haloC 1-6 alkyl;
R 6 is aryl optionally mono- or di-substituted with —CF 3 ;
R 7 is selected from hydrogen and methyl; and
R 8 is selected from hydrogen, —C 1-4 alkyl optionally substituted with halogen, and phenyl optionally mono or di-substituted with substituents selected from the group consisting of halogen, —C 1-6 alkyl, —C 1-6 alkoxy, and haloC 1-6 alkyl.
14. The compound according to claim 1 of Formula Ib
or a pharmaceutically acceptable salt thereof, wherein:
X is —CH 2 CH 2 CH 2 —;
A1 is phenyl;
A2is
R 1 , R 2 and R 9 are each independently selected from the group consisting of:
(a) hydrogen, and
(b) methyl;
R 3 is selected from the group consisting of:
(a) hydrogen,
(b) —CF 3 , and
(c) —O—(R 8 );
R 4 is selected from the group consisting of:
(a) hydrogen, and
(b) —CH 2 —C(═O)OH;
R 5 is selected from the group consisting of:
(a) —C 1-4 alkyl,
(b) pyridinyl,
(c) phenyl, and
(d) —C 3-6 cycloalkyl,
wherein the cycloalkyl portion of choice (d) is optionally substituted with methyl, and wherein the pyridinyl of choice (b) and the phenyl of choice (c) are optionally mono- or di-substituted with substituents selected from the group consisting of halogen, —C 1-6 alkyl, —CF 3 , —C 1-6 alkoxy and haloC 1-6 alkyl;
R 6 is phenyl optionally mono-substituted with —CF 3 ;
R 8 is selected from hydrogen, —C 1-4 alkyl optionally substituted with halogen, and phenyl optionally mono or di-substituted with substituents selected from the group consisting of halogen, —C 1-6 alkyl, —C 1-6 alkoxy, and haloC 1-6 alkyl.
15. The compound according to claim 2 of Formula Ic
or is a pharmaceutically acceptable salt thereof.
16. The compound according to claim 15 wherein R 9 is hydrogen.
17. The compound according to claim 1 selected from the group consisting of:
2-(4′-(3-(4-cyclohexyl-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(4-ethyl-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(5-oxo-4-propyl-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4′-(3-(4-cyclopentyl-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-(4′-(3-(4-(4-methylcyclohexyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-(4′-(3-(4-(3-methylcyclohexyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-(4′-(3-(4-(2-methylcyclohexyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4′-(3-(4-cyclohexyl-5-oxo-1-(4-(trifluoromethoxy)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(4-(2-fluorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-2′-methyl-[1,1′-biphenyl]-3-yl)acetic acid,
4′-(3-(4-(2-fluorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-2′-methyl-(4-trifluoromethyl)-,[1,1′-biphenyl]-3-carboxylic acid,
4-ethoxy-4′-(3-(4-(2-fluorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-2′-methyl-[1,1′-biphenyl]-3-carboxylic acid,
2-(4-ethoxy-4′-((((4-(2-fluorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl)amino)methyl)-[1,1′-biphenyl]-3-yl)acetic acid,
N-(6-(4-(3-(5-oxo-4-propyl-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)phenyl)pyridin-2-yl)benzenesulfonamide,
2-(4′-(3-(4-cyclopropyl-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-methoxy-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4′-(3-(4-(2-fluorobenzyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-methoxy-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(4-(2-fluorobenzyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4′-(3-(4-cyclopropyl-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-propoxy-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(5-oxo-4-phenyl-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl),[1,1′-biphenyl]-3-yl)acetic acid,
2-(4′-(3-(4-(2-chlorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(4-isobutyl-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(4-(3-fluorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4′-(3-(4-(2,5-difluorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4′-(3-(4-(2,6-difluorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4′-(3-(4-(4-(tert-butyl)phenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(4-(2-ethylphenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(4-(2-methoxyphenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4′-(3-(4-(2-chlorophenyl)-1-(4-isopropylphenyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4′-(3-(1-(4-(tert-butyl)phenyl)-4-(2,6-dichlorophenyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(4-(2-fluorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
4-ethoxy-4′-(3-(4-(2-fluorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-carboxylic acid,
2-(4-ethoxy-4′-(3-(4-(2-fluorophenyl)-5-oxo-1-(2-chloro-4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(4-(2-fluorophenyl)-5-oxo-1-(3-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(4-(2-(trifluoromethyl)phenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(1-(2-fluorophenyl)-5-oxo-4-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(1-(4-(trifluoromethyl)phenyl)-5-oxo-4-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(5-oxo-4-(pyridin-2-yl)-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-propoxy-4′-(3-(4-(2-fluorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(5-oxo-4-(o-tolyl)-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid, and
2-(4-ethoxy-4′-(3-(5-oxo-4-(pyridin-3-yl)-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
or a pharmaceutically acceptable salt thereof.
18. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
19. A method of treating cancer in a mammal which is negatively impacted by diminution in its metabolism of fatty acid oxidation, comprising administration of a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, to the mammal in need thereof.
20. The method according to claim 19 , wherein the cancer is selected from prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, and melanoma.
21. A method of treating cancer in a mammal comprising the administration of a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, to the mammal in need thereof.
22. The method according to claim 21 , wherein the cancer is prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, or melanoma.
23. A compound of claim 1 selected from the group consisting of:
2-(4′ -(3-(4-cyclohexyl-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(5-oxo-4-phenyl-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1-biphenyl]-3-yl)acetic acid,
2-(4′-(3-(4-(2-chlorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(4-(3-fluorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1-biphenyl]-3-yl)acetic acid,
2-(4′-(3-(4-(2,5-difluorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1-biphenyl]-3-yl)acetic acid,
2-(4-ethoxy-4′-(3-(4-(2-fluorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1-biphenyl]-3-yl)acetic acid, and
2-(4-ethoxy-4′-(3-(1-(4-(trifluoromethyl)phenyl)-5-oxo-4-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid, or a pharmaceutically acceptable salt thereof.